In this week’s platter, we look at what digital transformation means for 4 big pharma firms; we consider how AI and machine learning is deployed to forge advances in healthcare and diagnostics; and we pay attention to a potential game changer in adrenaline auto-injection devices. Enjoy….
Major pharma companies would be remiss to sit back and watch startups and Big Tech transform the landscape around them. Right now, the smartest incumbents are channeling the forces of disruption to their own ends, leading digital transformation in order to avoid ultimately being left behind. This article looks at how 4 big pharma companies are assessing the opportunities for digital transformation, and what it takes to stay ahead of the game.
Artificial intelligence (AI) holds much promise for the healthcare sector. AI has the potential to do everything from predicting readmissions, cutting human error and managing epidemics to assisting surgeons to carry out complex operations. Here we take a closer look at how 3 firms – BioXcel Therapeutics Inc., Microsoft Corp., Globus Medical Inc. – are leveraging AI to forge new advances in treating and tackling disease.
Doctors currently rely on CT and/or MRI scans to detect Small Vessel Disease (SVD), a common precursor to strokes and dementia, which reduces blood flow to the brain’s deep white matter connections. But observing changes in white matter over time can be difficult for the human eye, meaning that estimating the severity of the disease and, in turn, the likelihood of dementia or a stroke is a major challenge.
Scientists from Imperial College London and the University of Edinburgh have developed software capable of detecting dementia and stroke precursors using CT scans.
With a proven accuracy rate of 85% in predicting the severity of SVD, it is only a matter of time that precautionary scans will be taken at scale, analysed by the software, and the results are delivered in a fraction of the time. Saving time and hopefully saving money and improving patient outcomes in the process…
A team of South African biomedical engineers have built a cheap replacement for the EpiPen (adrenaline auto-injector) that could revolutionise the emergency treatment of anaphylaxis, a severe allergic reaction that can be triggered by food or insect bites. The replacement is a lot cheaper, has replaceable parts, has a longer shelf life and its needle length can be customized according to the dimensions of the patient. This could be a game changer…
Please log in again. The login page will open in a new window. After logging in you can close it and return to this page.